MENU

CLDX Stock Tickeron detected bullish Stock Pattern: Triangle Symmetrical Top CLDX on January 02, 2025, netting in a 5.18% gain over 6 days

A.I.dvisor
at Tickeron.com
Loading...
+5.18% Gain from a Successful pattern Triangle Symmetrical Top
CLDX - Celldex Therapeutics
Tickeron
Ticker: CLDX
Company: Celldex Therapeutics
Gain: +5.18%
Confirmed: 01/02/25
Succeeded: 01/06/25
Total length: 6 days
On December 31, 2024, A.I.dvisor detected a Triangle Symmetrical Top Pattern (Bullish) for Celldex Therapeutics (CLDX, $25.27). On January 02, 2025, A.I.dvisor confirmed the Bullish pattern, setting a target price of $27.63. 4 days later, on January 06, 2025, CLDX reached the target price resulting in a for traders who took a long position in the stock.

CLDX's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for CLDX turned positive on December 31, 2024. Looking at past instances where CLDX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 03, 2025. You may want to consider a long position or call options on CLDX as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CLDX moved above its 50-day moving average on January 03, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 59 cases where CLDX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLDX broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.008) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). CLDX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (144.928) is also within normal values, averaging (264.084).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CLDX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of immunotherapy technologies for the treatment of cancer and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
53 Frontage Road
Phone
+1 908 200-7500
Employees
160
Web
https://www.celldex.com